Figure 1.

Effects of dolutegravir (2.5–10 μg/mL) on the spontaneous lucigenin- and luminol-enhanced chemiluminescence responses of neutrophils. The results are expressed as the median peak chemiluminescence values in relative light units (RLU) measured 30–50 s after the addition of dolutegravir using Box and Whisker plots. Lucigenin-enhanced chemiluminescence (left graph): n = 5 donors with 9 replicates for each drug concentration and control system, and luminol-enhanced chemiluminescence (right graph): n = 6 with 30 replicates. “Background” refers to the unstimulated DMSO-treated control. p = 0.6395–p = 0.002 for comparison of the dolutegravir-treated systems with the unstimulated control system.